The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Somatostatin Market Research Report 2024
Synopsis
Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.
The global Somatostatin market was valued at US$ 336.6 million in 2023 and is anticipated to reach US$ 722.9 million by 2030, witnessing a CAGR of 11.4% during the forecast period 2024-2030.
Global Somatostatin key players include Merck (Schweiz) AG, SANOFI-AVENTIS FRANCE, Lyomark Pharma GmbH, ALFA WASSERMANN S.p.A., HYBIO, etc. Global top five manufacturers hold a share over 65%.
China is the largest market, followed by Europe and India.
This report aims to provide a comprehensive presentation of the global market for Somatostatin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin.
Report Scope
The Somatostatin market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Somatostatin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Somatostatin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck (Schweiz) AG
SANOFI-AVENTIS FRANCE
Lyomark Pharma GmbH
ALFA WASSERMANN S.p.A.
Polypeptide Laboratories, Inc
SAMARTH
UBPL
HYBIO
TianTaiShan
Yangtze River
Siyao
Shuangcheng
Hainan Zhonghe
SL PHARM
Wuhan Hualong
Qingdao Guoda
Chengdu Shengnuo
Longjin
Segment by Type
0.25mg/pcs
0.75mg/pcs
3mg/pcs
Segment by Application
Hormonal Disorder
Oncology
Metabolic Disorder
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Somatostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Somatostatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.
The global Somatostatin market was valued at US$ 336.6 million in 2023 and is anticipated to reach US$ 722.9 million by 2030, witnessing a CAGR of 11.4% during the forecast period 2024-2030.
Global Somatostatin key players include Merck (Schweiz) AG, SANOFI-AVENTIS FRANCE, Lyomark Pharma GmbH, ALFA WASSERMANN S.p.A., HYBIO, etc. Global top five manufacturers hold a share over 65%.
China is the largest market, followed by Europe and India.
This report aims to provide a comprehensive presentation of the global market for Somatostatin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin.
Report Scope
The Somatostatin market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Somatostatin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Somatostatin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck (Schweiz) AG
SANOFI-AVENTIS FRANCE
Lyomark Pharma GmbH
ALFA WASSERMANN S.p.A.
Polypeptide Laboratories, Inc
SAMARTH
UBPL
HYBIO
TianTaiShan
Yangtze River
Siyao
Shuangcheng
Hainan Zhonghe
SL PHARM
Wuhan Hualong
Qingdao Guoda
Chengdu Shengnuo
Longjin
Segment by Type
0.25mg/pcs
0.75mg/pcs
3mg/pcs
Segment by Application
Hormonal Disorder
Oncology
Metabolic Disorder
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Somatostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Somatostatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Somatostatin Market Overview
1.1 Product Overview and Scope of Somatostatin
1.2 Somatostatin Segment by Type
1.2.1 Global Somatostatin Market Value Comparison by Type (2024-2030)
1.2.2 0.25mg/pcs
1.2.3 0.75mg/pcs
1.2.4 3mg/pcs
1.3 Somatostatin Segment by Application
1.3.1 Global Somatostatin Market Value by Application: (2024-2030)
1.3.2 Hormonal Disorder
1.3.3 Oncology
1.3.4 Metabolic Disorder
1.3.5 Others
1.4 Global Somatostatin Market Size Estimates and Forecasts
1.4.1 Global Somatostatin Revenue 2019-2030
1.4.2 Global Somatostatin Sales 2019-2030
1.4.3 Global Somatostatin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Somatostatin Market Competition by Manufacturers
2.1 Global Somatostatin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Somatostatin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Somatostatin Average Price by Manufacturers (2019-2024)
2.4 Global Somatostatin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Somatostatin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Somatostatin, Product Type & Application
2.7 Somatostatin Market Competitive Situation and Trends
2.7.1 Somatostatin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Somatostatin Players Market Share by Revenue
2.7.3 Global Somatostatin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Somatostatin Retrospective Market Scenario by Region
3.1 Global Somatostatin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Somatostatin Global Somatostatin Sales by Region: 2019-2030
3.2.1 Global Somatostatin Sales by Region: 2019-2024
3.2.2 Global Somatostatin Sales by Region: 2025-2030
3.3 Global Somatostatin Global Somatostatin Revenue by Region: 2019-2030
3.3.1 Global Somatostatin Revenue by Region: 2019-2024
3.3.2 Global Somatostatin Revenue by Region: 2025-2030
3.4 North America Somatostatin Market Facts & Figures by Country
3.4.1 North America Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Somatostatin Sales by Country (2019-2030)
3.4.3 North America Somatostatin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Somatostatin Market Facts & Figures by Country
3.5.1 Europe Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Somatostatin Sales by Country (2019-2030)
3.5.3 Europe Somatostatin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Somatostatin Market Facts & Figures by Country
3.6.1 Asia Pacific Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Somatostatin Sales by Country (2019-2030)
3.6.3 Asia Pacific Somatostatin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Somatostatin Market Facts & Figures by Country
3.7.1 Latin America Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Somatostatin Sales by Country (2019-2030)
3.7.3 Latin America Somatostatin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Somatostatin Market Facts & Figures by Country
3.8.1 Middle East and Africa Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Somatostatin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Somatostatin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Somatostatin Sales by Type (2019-2030)
4.1.1 Global Somatostatin Sales by Type (2019-2024)
4.1.2 Global Somatostatin Sales by Type (2025-2030)
4.1.3 Global Somatostatin Sales Market Share by Type (2019-2030)
4.2 Global Somatostatin Revenue by Type (2019-2030)
4.2.1 Global Somatostatin Revenue by Type (2019-2024)
4.2.2 Global Somatostatin Revenue by Type (2025-2030)
4.2.3 Global Somatostatin Revenue Market Share by Type (2019-2030)
4.3 Global Somatostatin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Somatostatin Sales by Application (2019-2030)
5.1.1 Global Somatostatin Sales by Application (2019-2024)
5.1.2 Global Somatostatin Sales by Application (2025-2030)
5.1.3 Global Somatostatin Sales Market Share by Application (2019-2030)
5.2 Global Somatostatin Revenue by Application (2019-2030)
5.2.1 Global Somatostatin Revenue by Application (2019-2024)
5.2.2 Global Somatostatin Revenue by Application (2025-2030)
5.2.3 Global Somatostatin Revenue Market Share by Application (2019-2030)
5.3 Global Somatostatin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck (Schweiz) AG
6.1.1 Merck (Schweiz) AG Corporation Information
6.1.2 Merck (Schweiz) AG Description and Business Overview
6.1.3 Merck (Schweiz) AG Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck (Schweiz) AG Somatostatin Product Portfolio
6.1.5 Merck (Schweiz) AG Recent Developments/Updates
6.2 SANOFI-AVENTIS FRANCE
6.2.1 SANOFI-AVENTIS FRANCE Corporation Information
6.2.2 SANOFI-AVENTIS FRANCE Description and Business Overview
6.2.3 SANOFI-AVENTIS FRANCE Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 SANOFI-AVENTIS FRANCE Somatostatin Product Portfolio
6.2.5 SANOFI-AVENTIS FRANCE Recent Developments/Updates
6.3 Lyomark Pharma GmbH
6.3.1 Lyomark Pharma GmbH Corporation Information
6.3.2 Lyomark Pharma GmbH Description and Business Overview
6.3.3 Lyomark Pharma GmbH Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Lyomark Pharma GmbH Somatostatin Product Portfolio
6.3.5 Lyomark Pharma GmbH Recent Developments/Updates
6.4 ALFA WASSERMANN S.p.A.
6.4.1 ALFA WASSERMANN S.p.A. Corporation Information
6.4.2 ALFA WASSERMANN S.p.A. Description and Business Overview
6.4.3 ALFA WASSERMANN S.p.A. Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ALFA WASSERMANN S.p.A. Somatostatin Product Portfolio
6.4.5 ALFA WASSERMANN S.p.A. Recent Developments/Updates
6.5 Polypeptide Laboratories, Inc
6.5.1 Polypeptide Laboratories, Inc Corporation Information
6.5.2 Polypeptide Laboratories, Inc Description and Business Overview
6.5.3 Polypeptide Laboratories, Inc Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Polypeptide Laboratories, Inc Somatostatin Product Portfolio
6.5.5 Polypeptide Laboratories, Inc Recent Developments/Updates
6.6 SAMARTH
6.6.1 SAMARTH Corporation Information
6.6.2 SAMARTH Description and Business Overview
6.6.3 SAMARTH Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 SAMARTH Somatostatin Product Portfolio
6.6.5 SAMARTH Recent Developments/Updates
6.7 UBPL
6.6.1 UBPL Corporation Information
6.6.2 UBPL Description and Business Overview
6.6.3 UBPL Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 UBPL Somatostatin Product Portfolio
6.7.5 UBPL Recent Developments/Updates
6.8 HYBIO
6.8.1 HYBIO Corporation Information
6.8.2 HYBIO Description and Business Overview
6.8.3 HYBIO Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 HYBIO Somatostatin Product Portfolio
6.8.5 HYBIO Recent Developments/Updates
6.9 TianTaiShan
6.9.1 TianTaiShan Corporation Information
6.9.2 TianTaiShan Description and Business Overview
6.9.3 TianTaiShan Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 TianTaiShan Somatostatin Product Portfolio
6.9.5 TianTaiShan Recent Developments/Updates
6.10 Yangtze River
6.10.1 Yangtze River Corporation Information
6.10.2 Yangtze River Description and Business Overview
6.10.3 Yangtze River Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Yangtze River Somatostatin Product Portfolio
6.10.5 Yangtze River Recent Developments/Updates
6.11 Siyao
6.11.1 Siyao Corporation Information
6.11.2 Siyao Somatostatin Description and Business Overview
6.11.3 Siyao Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Siyao Somatostatin Product Portfolio
6.11.5 Siyao Recent Developments/Updates
6.12 Shuangcheng
6.12.1 Shuangcheng Corporation Information
6.12.2 Shuangcheng Somatostatin Description and Business Overview
6.12.3 Shuangcheng Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Shuangcheng Somatostatin Product Portfolio
6.12.5 Shuangcheng Recent Developments/Updates
6.13 Hainan Zhonghe
6.13.1 Hainan Zhonghe Corporation Information
6.13.2 Hainan Zhonghe Somatostatin Description and Business Overview
6.13.3 Hainan Zhonghe Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Hainan Zhonghe Somatostatin Product Portfolio
6.13.5 Hainan Zhonghe Recent Developments/Updates
6.14 SL PHARM
6.14.1 SL PHARM Corporation Information
6.14.2 SL PHARM Somatostatin Description and Business Overview
6.14.3 SL PHARM Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.14.4 SL PHARM Somatostatin Product Portfolio
6.14.5 SL PHARM Recent Developments/Updates
6.15 Wuhan Hualong
6.15.1 Wuhan Hualong Corporation Information
6.15.2 Wuhan Hualong Somatostatin Description and Business Overview
6.15.3 Wuhan Hualong Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Wuhan Hualong Somatostatin Product Portfolio
6.15.5 Wuhan Hualong Recent Developments/Updates
6.16 Qingdao Guoda
6.16.1 Qingdao Guoda Corporation Information
6.16.2 Qingdao Guoda Somatostatin Description and Business Overview
6.16.3 Qingdao Guoda Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Qingdao Guoda Somatostatin Product Portfolio
6.16.5 Qingdao Guoda Recent Developments/Updates
6.17 Chengdu Shengnuo
6.17.1 Chengdu Shengnuo Corporation Information
6.17.2 Chengdu Shengnuo Somatostatin Description and Business Overview
6.17.3 Chengdu Shengnuo Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Chengdu Shengnuo Somatostatin Product Portfolio
6.17.5 Chengdu Shengnuo Recent Developments/Updates
6.18 Longjin
6.18.1 Longjin Corporation Information
6.18.2 Longjin Somatostatin Description and Business Overview
6.18.3 Longjin Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Longjin Somatostatin Product Portfolio
6.18.5 Longjin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Somatostatin Industry Chain Analysis
7.2 Somatostatin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Somatostatin Production Mode & Process
7.4 Somatostatin Sales and Marketing
7.4.1 Somatostatin Sales Channels
7.4.2 Somatostatin Distributors
7.5 Somatostatin Customers
8 Somatostatin Market Dynamics
8.1 Somatostatin Industry Trends
8.2 Somatostatin Market Drivers
8.3 Somatostatin Market Challenges
8.4 Somatostatin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
